FDA Alignment Is a Starting Point, Not a Rare Disease Strategy for the European Market

Life science firms developing rare disease treatments for the U.S. market must integrate European regulatory requirements early in clinical trial design, as FDA alignment alone does not ensure approval in Europe. A new VCLS guide highlights the risks of assuming FDA agreement covers European expectations, citing delays caused by lack of European scientific advice that could have identified issues sooner.

This Wire brief sits within Fusion42's coverage of Biotech.